- Hyderabad: Road widening is no boon but a bane?
- Water tankers draining Goshamahal’s groundwater
- TG-RERA cracks down on slew of rogue developers across Hyderabad
- TPCC chief calls for grand success of Samvidhan Raksha March
- Power boost :Yadadri’s 800 MW 5th unit to be on stream in Dec
- Green SM entry sparks fare war
- 400 citizens urge Revanth to defer Global Summit amid El Nino
- Healthcare Pricing Summit 2026 organised
Sai Parenterals to acquire stake in Bion Therapeutics
In Short
The acquisition, expected to be completed before the end of November, will make Bion a step-down subsidiary of Sai Parenterals. The company has not disclosed the financial consideration or the exact stake being acquired.

Sai Parenterals to acquire stake in Bion Therapeutics
Hyderabad: Sai Parenterals Limited, through its wholly owned subsidiary SP Analytics Private Limited, has signed a definitive agreement to acquire a majority stake in Hyderabad-based Bion Therapeutics India Private Limited in an all-cash transaction.
The acquisition, expected to be completed before the end of November, will make Bion a step-down subsidiary of Sai Parenterals. The company has not disclosed the financial consideration or the exact stake being acquired.
Anil Kumar Karusala, Chairman &MD, Sai Parenterals, said:“This acquisition completes the platform we have been building. Over the past year we haveexpanded capacity at Unit III, begun construction of the critical-care injectable facility atGummadidala, consolidated all our research at Sai Prathyak, and strengthened the Noumed platform in Australia and New Zealand. Each of these strengthens what we are able to developand manufacture. Bion provides the route to take them to the Indian market directly,converting development capability into branded revenue.”
Laxman Prasad Shukla, MD, Bion Therapeutics, said: “Joining the Sai Parenterals Group addresses the constraint we have felt most acutely: accessto manufacturing depth and a development pipeline at the scale our market positionwarrants. Our team will continue to lead the business and its relationships. What changes isthe breadth of the portfolio they are able to take to market.”

